JP2023512763A5 - - Google Patents

Info

Publication number
JP2023512763A5
JP2023512763A5 JP2022547697A JP2022547697A JP2023512763A5 JP 2023512763 A5 JP2023512763 A5 JP 2023512763A5 JP 2022547697 A JP2022547697 A JP 2022547697A JP 2022547697 A JP2022547697 A JP 2022547697A JP 2023512763 A5 JP2023512763 A5 JP 2023512763A5
Authority
JP
Japan
Prior art keywords
item
crystalline form
anhydrous crystalline
compound
respect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022547697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512763A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/016414 external-priority patent/WO2021158663A1/en
Publication of JP2023512763A publication Critical patent/JP2023512763A/ja
Publication of JP2023512763A5 publication Critical patent/JP2023512763A5/ja
Priority to JP2025093285A priority Critical patent/JP2025120268A/ja
Pending legal-status Critical Current

Links

JP2022547697A 2020-02-06 2021-02-03 眼疾患の処置のための組成物 Pending JP2023512763A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025093285A JP2025120268A (ja) 2020-02-06 2025-06-04 眼疾患の処置のための組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062971002P 2020-02-06 2020-02-06
US62/971,002 2020-02-06
US202063010212P 2020-04-15 2020-04-15
US63/010,212 2020-04-15
PCT/US2021/016414 WO2021158663A1 (en) 2020-02-06 2021-02-03 Compositions for treatment of ocular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025093285A Division JP2025120268A (ja) 2020-02-06 2025-06-04 眼疾患の処置のための組成物

Publications (2)

Publication Number Publication Date
JP2023512763A JP2023512763A (ja) 2023-03-29
JP2023512763A5 true JP2023512763A5 (https=) 2024-02-09

Family

ID=77200537

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547697A Pending JP2023512763A (ja) 2020-02-06 2021-02-03 眼疾患の処置のための組成物
JP2025093285A Pending JP2025120268A (ja) 2020-02-06 2025-06-04 眼疾患の処置のための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025093285A Pending JP2025120268A (ja) 2020-02-06 2025-06-04 眼疾患の処置のための組成物

Country Status (11)

Country Link
US (2) US11873279B2 (https=)
EP (1) EP4100406A4 (https=)
JP (2) JP2023512763A (https=)
KR (1) KR20220143685A (https=)
CN (1) CN115103842A (https=)
AU (1) AU2021217358A1 (https=)
BR (1) BR112022015579A2 (https=)
CA (1) CA3168810A1 (https=)
IL (1) IL294873A (https=)
MX (1) MX2022009677A (https=)
WO (1) WO2021158663A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4050997A4 (en) * 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
CA3218398A1 (en) * 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
EP4329753A4 (en) 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES
WO2025137005A1 (en) * 2023-12-20 2025-06-26 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases
WO2025137007A1 (en) * 2023-12-20 2025-06-26 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4282793A (en) 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
JP2004525890A (ja) 2001-02-02 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤
US20030176356A1 (en) * 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI1013904A2 (pt) 2009-04-30 2016-07-19 Univ Midwestern método e composição para tratar cetoacidose diabética
US20110082151A1 (en) 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
KR20130050939A (ko) 2010-04-12 2013-05-16 가부시키가이샤 아루떼꾸 우에노 망막 질환의 치료 방법 및 이를 위한 안과용 조성물
MX390909B (es) 2013-12-19 2025-03-21 Tassos Georgiou Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.
MX2016009331A (es) * 2014-01-23 2016-10-26 Akebia Therapeutics Inc Composiciones y metodos para tratar enfermedades oculares.
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
CN107921036A (zh) 2015-05-29 2018-04-17 优势医疗公司 用于减少视力丧失的组合物和方法
JP6745594B2 (ja) * 2015-11-26 2020-08-26 持田製薬株式会社 ピラゾール誘導体の塩の結晶
WO2017217967A1 (en) 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
WO2018185516A1 (en) * 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
JP2020528082A (ja) 2017-07-17 2020-09-17 ロイズマン，キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
JP7134983B2 (ja) * 2017-09-15 2022-09-12 持田製薬株式会社 テトラヒドロナフチルウレア誘導体の結晶
WO2019210194A1 (en) 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
EP4050997A4 (en) 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases

Similar Documents

Publication Publication Date Title
JP2023512763A5 (https=)
JP4934653B2 (ja) Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
US10918656B2 (en) Therapeutic agent for dry eye characterized by being applied to eye of dry eye patient wearing soft contact lens
EA016227B1 (ru) Способ лечения офтальмологических неоваскулярных расстройств
JP5875585B2 (ja) 緑内障および高眼圧症の処置のためのアデノシンａ１アゴニスト
CN115103842A (zh) 用于治疗眼部疾病的组合物
US8501708B2 (en) Adenosine compounds and their use thereof
WO2019124489A1 (ja) セペタプロストとｅｐ２アゴニストとの組み合わせ医薬
JP2022520410A5 (https=)
CN102933593A (zh) 使用n6-环戊基腺苷（cpa）、cpa衍生物或其前药降低人眼内压的方法
US5055480A (en) Topically active ocular gem-diacylthiadiazole sulfonamide carbonic anhydrase inhibitors
CN111479567B (zh) 包含FP激动剂和β-阻断剂的青光眼的治疗剂
TW201309343A (zh) 經改善親水性藥物之藥物移行性之水性組成物
JP2024516829A5 (https=)
JP2012250947A (ja) アデノシン誘導体とβ受容体遮断薬の組合せ剤
JP2012250953A (ja) アデノシン誘導体とα２受容体作動薬の組合せ剤
TWI917308B (zh) 歐米德尼培（Ｏｍｉｄｅｎｅｐａｇ）之組合
JP2012250950A (ja) アデノシン誘導体とプロスタグランジン類の組合せ剤
JP2023110029A (ja) オミデネパグの組合せ
JP2012250952A (ja) アデノシン誘導体とＲｈｏキナーゼ阻害剤の組合せ剤
JP2012250948A (ja) アデノシン誘導体と炭酸脱水酵素阻害剤の組合せ剤